Initial Case Quality Control Form

Liver (LIHC)

Instructions: This form should be completed for all cases submitted for TCGA, prior to the shipment of samples to the BCR.

Questions regarding this form should be directed to the Tissue Source Site's primary Clinical Outreach Contact at the BCR.

Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis

	tea by the TSS through histor ts to the TSS by means of a for													e 133 authorizes the BCR to report these patient lress.
	Source Site (TSS):				_									
	is TSS received permission fr Provided time intervals must be								for req	uested o	dates or	this fo	rm? 🗆	Yes □ No
Tumo	or Information: The following	ng secti	ons are	to be pr	ovided	by a Pa	thologi	st						
#	Question					E	intry Alt	ernativ	es					Working Instructions
1	Histologic Subtype of Tumor Submitted for TCGA	☐ Fib	patocell prolamel patocho	llar hep	atocellı	ılar car								Indicate the confirmed diagnosis of the tumor submitted for TCGA. 3081934
2	Tumor Type	□ Pri	imary (p	rimary ι	ıntreated	d malign	ant biosį	pecimen)					Indicate the type of tumor submitted for TCGA. 3288124 This is a biospecimen that has not been treated with chemotherapy or radiation prior to resection.
3	Anatomic Organ Sub- Division of Frozen Biospecimen		□ Liver								Indicate the anatomic site of the frozen tumor biospecimen submitted for TCGA. $\underline{2008006}$			
Date	of Cancer Sample Procure	ment												
4	Month of Cancer Sample Procurement	□ 01	1 02	1 03	1 04	1 05	1 06	1 07	□ 08	1 09	1 0	1 1	1 2	Provide the month of the procedure performed to obtain the malignant tissue submitted for TCGA. 3008197
5	Day of Cancer Sample Procurement	□ 01 □ 13 □ 25	□ 02 □ 14 □ 26	□ 03 □ 15 □ 27	□ 04 □ 16 □ 28	□ 05 □ 17 □ 29	□ 06 □ 18 □ 30	□ 07 □ 19 □ 31	□ 08 □ 20	□ 09 □ 21	□ 10 □ 22	□ 11 □ 23	□ 12 □ 24	Provide the day of the procedure performed to obtain the malignant tissue submitted for TCGA. $\underline{3008195}$
6	Year of Cancer Sample Procurement													Provide the year of the procedure performed to obtain the malignant tissue submitted for TCGA. 3008199
7	Method of Cancer Sample Procurement	☐ Tra	rgical re ansplant parosco her metl	t pic biop	osy	ecify)								Indicate the procedure performed to obtain the malignant tissue submitted for TCGA. 3103514
8	Other Method of Cancer Sample Procurement													If the procedure performed to obtain the malignant tissue is not included in the provided list, specify the procedure. 2006730
9	Country Where Cancer Sample was Procured													Provide the country where the tissue submitted for TCGA was procured. 3203072

Initial Case Quality Control Form Liver (LIHC)

#	Question	Entry Alternatives	Working Instructions
10	Race	 □ American Indian or Alaska Native A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. □ Asian	Provide the patient's race using the defined categories. 2192199
11	Ethnicity	 Not Hispanic or Latino A person not meeting the definition of Hispanic or Latino. Hispanic or Latino A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. Not Evaluated Not provided or available. Unknown	Provide the patient's ethnicity using the defined categories. 2192217
12	Vessel Used	☐ Cryovial ☐ Cassette ☐ Other, specify ☐ Biospecimen Storage Bag ☐ Cryomold	Indicate the type of vessel used to ship the tissue to the Biospecimen Core Resource (BCR) for TCGA. 3081940
13	Other Vessel Used		If the vessel used to ship the tissue to the BCR is not included in the provided list, specify the vessel used. 3288137
14	Is tumor sample being submitted for macrodissection?	□ Yes □ No	Indicate whether the tumor sample submitted to the BCR is intended to undergo macrodissection after the BCR receives the sample. 3288488
15	Was sample prescreened at site?	□ Yes □ No	Indicate whether the sample submitted to the BCR was prescreened at the TSS. 3081942
Tum	or Slides Submitted		
<u>16</u>	Types of Slides Submitted	□ Physical Top Slide □ Digital Top Slide Image □ Physical FFPE Slide □ Digital FFPE Slide Image	Indicate the type(s) of slide(s) submitted to the BCR. TBD Top Slide Definition: Slide cut directly from frozen biospecimen = mirror image of inked surface
<u>17</u>	Slide/Digital Image ID #		Provide the slide ID for each slide (physical and digital image) submitted to the BCR. 2321277

Initial Case Quality Control Form Liver (LIHC)

V4.02 091112

#	Question	Entry Alternatives	Working Instructions							
Tume	umor Information If the TSS is submitting multiple pieces of the same primary tumor for this case; complete the following information for each piece of tumor sent to the BCR.									
<u>18</u>	Tumor Identifier		Provide the TSS unique tumor ID. If multiple pieces of tumor are submitted, each tumor needs a unique ID. 3288096							
<u>19</u>	Weight of Frozen Tumor	(mg)	Provide the weight of the tumor sample submitted for TCGA. 3081946 Weight can be estimated based on the size of the tumor submitted.							
<u>20</u>	Tumor Nuclei %	(%)	Provide the percent of tumor nuclei for the sample submitted for TCGA. 2841225 Check with the BCR to confirm the current acceptable TCGA metrics.							
22	Necrosis %	(%)	Provide the percent of necrosis for the sample submitted for TCGA. 2841237 Check with the BCR to confirm the current acceptable TCGA metrics.							
Norm	nal Information A normal co	ontrol must be present to qualify.								
23	Type(s) of Normal Control Check all that apply	☐ Whole Blood ☐ Extracted DNA from Blood ☐ Buffy Coat ☐ Non-Neoplastic Control Tissue*	Indicate the type of normal control submitted for this case. 3081936 *Non-neoplastic Control Tissue may only be submitted with NCI approval.							
Norr	nal Control: Whole Blood									
24	Method of Normal Sample Procurement	□ Blood Draw	Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147							
25	Month of Normal Sample Procurement	01 02 03 04 05 06 07 08 09 10 11 12	Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195							
26	Day of Normal Sample Procurement	□ 01 □ 02 □ 03 □ 04 □ 05 □ 06 □ 07 □ 08 □ 09 □ 10 □ 11 □ 12 □ 13 □ 14 □ 15 □ 16 □ 17 □ 18 □ 19 □ 20 □ 21 □ 22 □ 23 □ 24 □ 25 □ 26 □ 27 □ 28 □ 29 □ 30 □ 31	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196							
27	Year of Normal Sample Procurement		Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197							
<u>28</u>	Normal Identifier		Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138							
Norr	nal Control: Buffy Coat/ Lyn	nphocytes								
29	Normal Control Type	☐ Buffy Coat ☐ Lymphocytes	Indicate the type of normal control submitted for TCGA. 3081936							
30	Method of Normal Sample Procurement	□ Blood Draw	Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147							

Initial Case Quality Control Form Liver (LIHC)

#	Question					E	ntry Alt	ernativ	es					Working Instructions
31	Month of Normal Sample Procurement	1 01	1 02	1 03	1 04	1 05	1 06	1 07	□ 08	1 09	1 0	1 1	1 2	Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195
32	Day of Normal Sample Procurement	□ 01 □ 13 □ 25	□ 02 □ 14 □ 26	□ 03 □ 15 □ 27	□ 04 □ 16 □ 28	□ 05 □ 17 □ 29	□ 06 □ 18 □ 30	□ 07 □ 19 □ 31	□ 08 □ 20	□ 09 □ 21	□ 10 □ 22	□ 11 □ 23	□ 12 □ 24	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196
33	Year of Normal Sample Procurement													Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197
<u>34</u>	Normal Identifier													Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138
Norn	nal Control: Extracted DNA	from B	lood											
35	Method of Normal Sample Procurement	□Blo	ood Drav	V										Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147
36	Month of Normal Sample Procurement	1 01	1 02	1 03	□ 04	1 05	□ 06	1 07	□ 08	□ 09	1 0	1 1	1 2	Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195
37	Day of Normal Sample Procurement	□ 01 □ 13 □ 25	□ 02 □ 14 □ 26	□ 03 □ 15 □ 27	□ 04 □ 16 □ 28	□ 05 □ 17 □ 29	□ 06 □ 18 □ 30	□ 07 □ 19 □ 31	□ 08 □ 20	□ 09 □ 21	□ 10 □ 22	□ 11 □ 23	□ 12 □ 24	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196
38	Year of Normal Sample Procurement													Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197
<u>39</u>	Normal Identifier													Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138
40	Extracted DNA Quantity								(μg)					Provide the quantity (μg) of the normal control sample sent to the BCR for TCGA. 3288185
41	Extracted DNA Quantification Method													Provide the quantification method of the normal control sample sent to the BCR for TCGA. 3288186
<u>42</u>	Extracted DNA Concentration				_				_(µg/µ	L)				Provide the concentration ($\mu g/\mu L$) of the normal control sample sent to the BCR for TCGA. <u>3288187</u>
43	Extracted DNA Volume								(μL)					Provide the volume (μ L) of the normal control sample sent to the BCR for TCGA. 3288188
Norn	nal Control: Non-Neoplastic	: Contro	ol Tissu	e										
44	Method of Normal Sample Procurement	□ Tra	rgical re ansplant paroscoj ner Meth	; pic biop		cify)								Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147

V4.02 091112

Initial Case Quality Control FormLiver (LIHC)

#	Question					E	ntry Alt	ernativ	es					Working Instructions
45	Other Method of Normal Sample Procurement													If the procedure performed to obtain the normal sample is not included in the provided list, specify the procedure. $\underline{3288151}$
46	Month of Normal Sample Procurement	□ 01	1 02	1 03	1 04	1 05	1 06	1 07	□ 08	□ 09	1 0	1 1	1 2	Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195
47	Day of Normal Sample	□ 01 □ 13 □ 25	□ 02 □ 14 □ 26	□ 03 □ 15 □ 27	□ 04 □ 16 □ 28	□ 05 □ 17 □ 29	□ 06 □ 18 □ 30	□ 07 □ 19 □ 31	□ 08 □ 20	□ 09 □ 21	□ 10 □ 22	□ 11 □ 23	□ 12 □ 24	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196
48	Year of Normal Sample Procurement													Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197
<u>49</u>	Normal Identifier													Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138
<u>50</u>	Anatomic Site of Non- Neoplastic Control Tissue	□ Liv	er ner (plea	ase spec	cify)									If the normal control type is normal tissue, indicate the anatomic site of the non-neoplastic control tissue submitted for TCGA. 3081938
<u>51</u>	Other Site of Non- Neoplastic Control Tissue													If the normal control type is normal tissue and the anatomic site is not included in the provided list, specify the site of the non-neoplastic control. 3288189
<u>52</u>	Proximity of Normal Tissue to Tumor	□ Dis	stal (> 20	cm) fro	m the p	rimary t	tumor							If the normal control type is normal tissue, confirm that the submitted normal tissue was at least 2cm away from the primary tumor. 3088708 Adjacent (≤ 2cm) Normal Tissue is not accepted for this tissue type. Unknown Normal Tissue is not acceptable for this tissue type.
<u>53</u>	Normal Slide ID#													If the normal control type is normal tissue, provide the slide ID for the physical top slide OR the digital slide image of the normal control being sent to the BCR. 3288217

Verification: By providing the below information, the Principal Investigator acknowledges that the information provided by the institution is true and correct and has been quality controlled.

Pathology Review

Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.

54	Name of Pathologist	 Provide the name of the Pathologist that provided the information for all previous sections. 3288225
55	Date of Pathologist Review	Provide the date of the pathology review performed by the TSS pathologist above. 3288224

V4.02 091112

Initial Case Quality Control Form Liver (LIHC)

#	Question	Entry Alternatives	Working Instructions
Prin	cipal Investigator/Authoriz	zed Designee Confirmation	
56	Percent Tumor Nuclei meets TCGA metrics?	□ Yes □ No	Confirm that the malignant sample submitted to the BCR meets the current tumor nuclei metrics for TCGA. 3288520 Check with the BCR to confirm the current acceptable TCGA metrics.
57	Percent Necrosis meets TCGA metrics?	□ Yes □ No	Confirm that the malignant sample submitted to the BCR meets the current necrosis metrics for TCGA. 3288524 Check with the BCR to confirm the current acceptable TCGA metrics.
58	De-Identified Pathology Report Submitted?	□ Yes □ No	Confirm that a de-identified pathology report will be sent to BCR prior to or with the shipment of the physical samples. 3288292
59	Is the histologic diagnosis on the CQCF (as determined by the TSS pathology review of the TCGA frozen section top slide) consistent with the histology listed in the final diagnosis on the pathology report?	□ Yes □ No	Confirm that the diagnosis provided on this CQCF for the tumor sample being submitted to TCGA is consistent with the diagnosis found on the patient's pathology report for the tumor being sent to the BCR. 3288300 If "yes," skip related question below. The diagnosis is considered to be consistent if at least one of the following criteria are met: 1) Diagnosis on the CQCF is identical to the pathology report for the tumor being sent to the BCR. 2) Diagnosis on the CQCF includes as least one of the subtypes listed on the pathology report and all subtypes on the pathology report are acceptable for TCGA. 3) Diagnosis on the CQCF is "histology, NOS" (i.e., Adenocarcinoma, NOS) and the pathology report lists a specific subtype within the same histologic group 4) Diagnosis on the CQCF indicates "Mixed Subtype" and the pathology report lists two or more acceptable subtypes, provided that percent subtype(s) meet applicable TCGA disease-specific requirements.
60	If the diagnosis on this form is not consistent with the provided pathology report, indicate the reason for the inconsistency.	 □ Macrodissection performed at TSS to select for a region containing an acceptable TCGA diagnosis (see note at right) □ Pathology analysis at TSS determined a specific histological subtype different from original pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) 	If the diagnosis provided on this form is not consistent with the diagnosis found on the pathology report provided, specify a reason for this inconsistency. 3288315 If a TSS pathology review of the TCGA committed sample resulted in a different histological subtype than what is documented on the original pathology report, an amendment to the pathology report should be submitted when the sample is shipped to the BCR; or in the absence of an amended pathology report, the TSS must complete and submit an electronic copy of the "TCGA Pathologic Diagnosis Discrepancy Form". In the case of diagnosis modifications, institution protocol should be followed for proper quality assurance.
61	History of Other Malignancy	□ None □ History of Prior Malignancy □ History of Synchronous/ Bilateral Malignancy □ Both History of Synchronous/ Bilateral and Prior Malignancy	Indicate whether the patient has a history of malignancies. If the patient has any history, including synchronous or bilateral malignancies, please complete an "Other Malignancy Form" for each malignancy diagnosed prior to the procurement of the tissue submitted for TCGA. 3382736 If the patient has a history of multiple diagnoses of basal

Page 7

Initial Case Quality Control Form

V4.	02	091	112

Liver (LIHC)

#	Question		Entry Alternatives	Working Instructions
				orsquamous cell skin cancer, complete an OMF for the first diagnosis for each of these types.
62	History of Neoadjuvant Treatment <i>for Tumor</i> <i>Submitted for TCGA</i>	None Radiation prior to sample procu Pharmaceutical treatment prior Both pharmaceutical treatment		Indicate whether the patient received therapy for this cancer prior to the sample procurement of the tumor submitted for TCGA . If the patient did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instruction. 3382737 *Systemic therapy and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to the procurement of the sample submitted for TCGA are exclusionary.
63	Consent Status	☐ Consented ☐ Exen☐ Deceased ☐ Waiv	nption 4* ver*	Indicate whether the patient was formally consented, consented by death, or if the case has an exemption or waiver for consent. 3288361 *Exemptions and waivers for consent must be approved by NCI.
Date	of Consent			
64	Month of Consent	01 02 03 04 0	05 06 07 08 09 010 011 012	If the patient was formally consented, provide the month of consent. $\underline{3081955}$
65	Day of Consent	13 □ 14 □ 15 □ 16 □	05 06 07 08 09 10 11 12 17 18 19 20 21 22 23 24 29 30 31	If the patient was formally consented, provide the day of consent. 3081957
66	Year of Consent			If the patient was formally consented, provide the year of consent. 3081959
Date	of Death Do not complete da	of death, if patient formally con	nsented.	
67	Month of Death	01 🗆 02 🗆 03 🗆 04 🗖	05 06 07 08 09 010 011 012	If the patient consented by death, provide the month of death. $\underline{2897026}$
68	Day of Death	13 □ 14 □ 15 □ 16 □	05 06 07 08 09 10 11 12 17 18 19 20 21 22 23 24 29 30 31	If the patient consented by death, provide the day of death. 2897028
69	Year of Death			If the patient consented by death, provide the year of death. $\underline{2897030}$

Principal Investigator or Designee Signature

Print Name

Date

Initial Case Quality Control Form

Liver (LIHC)

V4.02 091112

Time Intervals: The following questions are only to be answered if the Tissue Source Site is unable to provide the dates requested on this form.

#	Question	Entry Alternatives	Working Instructions
ii	Number of Days from Date of Diagnosis to Date of Cancer Sample Procurement	days	Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the procedure that produced the malignant sample submitted for TCGA. 3288495
iii	Number of Days from Date of Diagnosis to Normal Sample Procurement	days	Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the procedure that produced the normal control sample submitted for TCGA. 3288496
iv	Number of Days from Date of Diagnosis to Date of Pathological Review	days	Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the pathological review performed as part of the submission process for TCGA. 3288497
v	Number of Days from Date of Diagnosis to Date of Consent	days	If the patient formally consented, provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the patient's formal consent. 3288498
vi	Number of Days from Date of Diagnosis to Date of Death	days	If the patient consented by death, provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the patient's death. 3288499 Do not complete days to death, if patient formally consented.